Skip to main content

SRPT

Stock
Health Care
Biotechnology

Performance overview

SRPT Price
Price Chart

Forward-looking statistics

Beta
0.70
Risk
46.78%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.

Company info

SectorHealth Care
IndustryBiotechnology
Employees1K
Market cap$11.7B

Fundamentals

Enterprise value$2.5B
Revenue$2.2B
Revenue per employee—
Profit margin-11.12%
Debt to equity118.73

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$2.64
Dividend per share—
Revenue per share$23.28
Avg trading volume (30 day)$111M
Avg trading volume (10 day)$98M
Put-call ratio—

Macro factor sensitivity

Growth+0.9
Credit+5.1
Liquidity+0.2
Inflation-0.3
Commodities-1.1
Interest Rates-2.8

Valuation

Dividend yield0.00%
PEG Ratio1.53
Price to sales0.77
P/E Ratio1.53
Enterprise Value to Revenue1.13
Price to book1.51

Upcoming events

Next earnings dayMay 7, 2025
Next dividend day—
Ex. dividend day—

News

Did The FDA Make A Mistake? Sarepta's Elevidys Approval Under Scrutiny

The Food and Drug Administration (FDA) on Tuesday said it is investigating the risk of acute liver failure with serious outcomes, including hospitalization and death, following Sarepta Therapeutics, Inc.'s SRPT Elevidys treatment and evaluating the need for further regulatory action.

Benzinga (June 25, 2025)
SRPT Stock: What's Happening With Sarepta Therapeutics?

Sarepta Therapeutics (NASDAQ: SRPT) suffered a devastating blow on Monday, June 16 when its stock plummeted 42% following news of a second patient death linked to its Duchenne muscular dystrophy gene therapy, Elevidys. The biotechnology company and its global partner Roche immediately suspended commercial and clinical use of the treatment in non-ambulatory patients pending a comprehensive safety review.

Forbes (June 17, 2025)
Sarepta's gene therapy medicine kills patient, CEO suspends full year guidance

CNBC's Angelica Peebles reports on the latest news regarding Sarepta.

CNBC Television (June 16, 2025)
SRPT Plummets on Second Patient Death After DMD Gene Therapy Infusion

Sarepta's shares sink as second Elevidys-linked death triggers safety concerns, dosing halts and trial pauses.

Zacks Investment Research (June 16, 2025)
Sarepta Therapeutics, KULR Technology Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were higher this morning, with the Dow futures gaining more than 150 points on Monday.

Benzinga (June 16, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free